Craddock, C., Houlton, A., Ferguson, P., Raghavan, M., Fox, S., Dudley, L., . . . Vyas, P. (2016). Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. American Society of Hematology.
Citace podle Chicago (17th ed.)Craddock, C., et al. Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. American Society of Hematology, 2016.
Citace podle MLA (9th ed.)Craddock, C., et al. Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. American Society of Hematology, 2016.